ASCO GU24 special: Prof. Nizar Tannir shares CheckMate 214 results
EAU Podcasts - A podcast by European Association of Urology - Sundays
Categories:
In this podcast, UROONCO RCC chief editor Dr. Carmen Mir interviews Prof. Nizar Tannir from the University of Texas, MD Anderson Cancer Center, USA, on the long-term follow-up data from the phase 3 CheckMate 214 trial: Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC). Prof. Tannir summarises the history and stability of the Checkmate 214 trial results over the last 8 years, before discussing the latest data from his ...
